IMM Investment

IMM Investment is one of the more established names in Korean private capital, operating across venture, growth equity, and infrastructure from a Seoul base with a reputation for taking concentrated positions in mid-cap industrial and life sciences companies. Within healthcare the firm is most active in biotech, pharma and therapeutics, and life sciences tools, with check sizes and stage focus that put it firmly in the growth-oriented part of the Korean ecosystem.

The IMM thesis emphasizes operational value creation in companies that have moved past the early scientific risk and need capital and operating discipline to scale globally. That posture leads to investments in late-stage biotech, contract development and manufacturing organizations, specialty pharma, and life sciences tools companies with meaningful revenue or pre-commercial assets. The firm is less active in highly speculative early-stage discovery work, preferring to enter when there is a credible product or platform thesis backed by clinical or commercial evidence. AI and computational biology fit within scope when they are embedded in companies with real assets rather than as standalone software stories.

Check sizes range from five to twenty-five million dollars, with the firm participating from Series A through growth rounds and into pre-IPO situations. The geographic focus is Korea with frequent international activity in companies where Korean founders or manufacturing capacity intersect with global commercial markets. IMM’s broader private equity practice gives it institutional muscle that pure venture firms often lack, particularly around governance, M&A structuring, and post-investment operational improvement.

The team includes senior partners with operating and private equity backgrounds, which shapes how diligence and post-investment engagement are run. Founders should expect a more rigorous look at financial controls, manufacturing operations, and management bandwidth than many venture-only firms apply at the same stage.

In practice, IMM Investment is best suited to founders running companies that have crossed the threshold from science risk to execution risk. The firm’s introductions are most useful for industrial partnerships, manufacturing capacity, and corporate development conversations with Korean and international strategics in pharma and life sciences. Post-investment engagement tends to involve board representation, hands-on participation in financial and operational governance, and active involvement in major hires and capital raises. Founders looking for a true seed-stage thinking partner will find IMM tonally heavier than peers focused on early-stage venture, but for biotech, pharma, and life sciences tools companies in Korea or the broader region that need a partner with private equity sophistication and a deep bench in industrial scale-up, IMM is among the more substantive options. The firm’s track record of supporting companies through commercialization and exit, including IPOs and strategic transactions, gives founders a reasonable expectation of what the relationship looks like over time.